(Adds details throughout)
Nov 27 (Reuters) -
Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episodes compared to a placebo, in a mid-stage study.
Still, the company said it was actively exploring future development of the drug candidate, XEN1101, as a treatment for MDD.
Xenon said the study data was compelling, building upon the ongoing late-stage study for the use of XEN1101 in treating epilepsy. (Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)